On February 28, 2006, sanofi-aventis announced that its fast-actingApidra (insulin glulisine [rDNA origin] injection) is now available byprescription in the United States. Apidra was granted FDA approval inApril 2004.
Sanofi-aventis says that Apidra should be used in regimens thatinclude a longer-acting insulin or basal insulin analogue such asLantus.
Sanofi-aventis also announced that Apidra cartridges are nowavailable for use with the OptiClik insulin pen, which is also currentlyapproved for use with Lantus.
In a sanofi-aventis press release, Richard M. Bergenstal, MD,executive director of the International Diabetes Center at ParkNicollet, Minneapolis, Minnesota, says, “Controlling mealtimeblood sugar spikes is a crucial part of managing diabetes. Apidra is awelcome addition to the armamentarium of all healthcare professionalswho treat adults with diabetes.”